Yahoo Finance 
Angelman Syndrome (AS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary. This reports provides a data-driven overview of the current and future competitive landscape in AS therapeutics. - There will be more than 313,981 diagnosed prevalent cases of AS in 2023 in the 16 major markets.
New York, May 02, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Angelman Syndrome (AS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" - https://www.reportlinker.com/p06454299/?utm_source=GNW
Summary
This reports provides a data-driven overview of the current and future competitive landscape in AS therapeutics.
- There will be more than 313,981 diagnosed prevalent cases of AS in 2023 in the 16 major markets.
- The marketed drugs space for AS is poor as there are no therapies currently approved for the treatment of the disease.
- R&D activity in AS is very sparse, with only one drug in late-stage development.
- Commercial sponsors dominated the clinical trials space in AS over the past 10 years, with Ovid Therapeutics sponsoring the highest number of clinical trials.
- During the past 12 months, three merger and acquisition transactions involving companies developing AS assets were successfully completed.
Scope
Angelman Syndrome: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the AS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06454299/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
